IP Library Granted Patent US 12,734,128
Granted Patent B2
US 12,734,128 · App. 17/774,126 · Granted Sep 15, 2026

Gastric residence systems having a filament for improved gastric residence

Inventors: Rosemary Kanasty (Cambridge, MA); Tyler Grant (Arlington, MA); Jung Hoon Yang (Watertown, MA); David C. Dufour (Watertown, MA); Erik Robert Waldemar Ryde (Watertown, MA)
Assignee: Nortiva Bio, Inc.
A61K9/0065A61K47/10A61K47/12A61K47/32A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,734,128
App. No.
17/774,126
Granted
Sep 15, 2026
Kind
B2
Abstract

Provided are gastric residence systems comprising: a core; a plurality of arms connected to the core at a proximal end through a plurality of linker components, one linker component of the plurality of linker components corresponding to each arm of the plurality of arms, and the plurality of arms extending radially from the proximal end, and a filament circumferentially connecting each arm of the plurality of arms.

Claims (29)

1 . A gastric residence system comprising:

a core;

a plurality of arms connected to the core at a proximal end through a plurality of linker components, one linker component of the plurality of linker components corresponding to each arm of the plurality of arms, and the plurality of arms extending radially from the proximal end; and

a filament circumferentially connecting each arm of the plurality of arms.

2 . The gastric residence system of claim 1 , wherein the filament circumferentially connects a distal end of each arm of the plurality of arms.

3 . The gastric residence system of claim 1 , wherein at least one arm of the plurality of arms comprises a segment comprising 40-60% loading of an active pharmaceutical ingredient.

4 . The gastric residence system of claim 1 , wherein the gastric residence system is configured to be folded during administration and is configured to assume an open configuration when in a patient's stomach and the linker component degrades, dissolves, disassociates, or mechanically weakens in a gastric environment.

5 . The gastric residence system of claim 4 , wherein the core undergoes elastic deformation when the gastric residence system is in the folded configuration and recoils when the gastric residence system assumes the open configuration.

6 . The gastric residence system of claim 1 , wherein the force required to compress the gastric residence system into a configuration small enough to pass through an opening having a diameter of 20 mm is at least one and a half times greater than the force required to compress a gastric residence system without a filament into a configuration small enough to pass through the opening, as measured using a radial test.

7 . The gastric residence system of claim 2 , wherein the pullout force required to separate the filament from the distal end of a first arm of the plurality of arms is greater than 1N when measured after incubating the gastric residence system in an environment of pH 1.6 for 3 days and less than 2N when measured after incubating the gastric residence system in an environment of pH 6.5 for 3 days.

8 . The gastric residence system of claim 1 , wherein the distal end of each arm of the plurality of arms comprises an enteric material comprising a polymer, an enteric polymer, a plasticizer, and an acid.

9 . The gastric residence system of claim 1 , wherein the filament comprises one or more of an elastic polymer, a biosorbable polymer, and a plasticizer.

10 . The gastric residence system of claim 8 , wherein the polymer comprises polycaprolactone or TPU, the enteric polymer comprises hydroxypropylmethylcellulose acetate succinate, the plasticizer comprises propylene glycol, the acid comprises stearic acid.

11 . The gastric residence system of claim 1 , wherein the distal end of each arm comprises a notch and the filament is positioned within the notch of each distal end.

12 . The gastric residence system of claim 1 , wherein each arm of the plurality of arms comprises a first segment comprising a first polymer composition and a second segment comprising a second polymer composition, wherein the first segment has a stiffness greater than a stiffness of the second segment, as measured using a 3-point bending test per ASTM D790.

13 . The gastric residence system of claim 12 , wherein the force required to compress the gastric residence system into a configuration small enough to pass through an opening having a diameter of 20 mm is at least 1.2 times greater than the force required to compress a gastric residence system having arms comprising only a first polymer composition into a configuration small enough to pass through the opening, as measured using an iris testing mechanism.

14 . The gastric residence system of claim 12 , wherein the first polymer composition comprises one or more of PCL, PLA, PLGA, HPMCAS, and TPU and the second polymer composition comprises one or more of a polyurethane, a polyether-polyamide copolymer, a thermoplastic elastomer, a thermoplastic polyurethane, polycaprolactone polylactic acid copolymer, a poly (trimethylene carbonate), a polyglycerol sebacate, and a silicone.

15 . The gastric residence system of claim 12 , wherein the first segment comprises 20-50% of a length of at least the first arm of the plurality of arms, the length being measured from a proximal end of the first arm, the proximal end being proximate to the core, to a distal end of the first arm and the second segment comprises 50-80% of a length of at least the first arm of the plurality of arms, the length being measured from a proximal end of the first arm, the proximal end being proximate to the core, to a distal end of the first arm.

16 . The gastric residence system of claim 12 , wherein a number of fatigue cycles required to break the gastric residence system is at least 25% greater than a number of fatigue cycles required to break a gastric residence system with arms comprising only a first polymer composition, as measured using a double funnel test.

17 . The gastric residence system of claim 1 , wherein the gastric residence system is configured to be encapsulated with a capsule when the gastric residence system is in a folded configuration to form a gastric residence dosage form suitable for administering to a patient, and the gastric residence dosage form is configured to release the gastric residence system in a stomach of the patient, allowing the gastric residence to assume an open configuration.

18 . The gastric residence system of claim 1 , wherein the gastric residence system is used to treat a human.

19 . A gastric residence system comprising:

a plurality of arms connected at a proximal end, the plurality of arms extending radially from the proximal end; and

a filament circumferentially connecting a distal end of each arm of the plurality of arms.

20 . A method of manufacturing a gastric residence system comprising:

preparing gastric residence system comprising a plurality of arms connected to a core at a proximal end through a plurality of linker components, one linker component of the plurality of linker components corresponding to each arm of the plurality of arms, and the plurality of arms extending radially;

notching each arm of the plurality of arms to form a notch in each arm;

wrapping a filament circumferentially around the gastric residence system such that the filament is positioned within each notch of each arm; and

closing each notch to secure the filament within each notch.

Assignments (7)
CHANGE OF NAME Recorded Nov 19, 2025
From: ISP ACQUISITION COMPANY, INC.
To: NORTIVA BIO, INC.
Reel/Frame 073607/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2025
From: LYNDRA THERAPEUTICS, INC.
To: ISP ACQUISITION COMPANY, INC.
Reel/Frame 073610/0424 →
RELEASE OF SECURITY INTEREST Recorded Dec 28, 2023
From: ISP HOLDINGS LLC
To: LYNDRA THERAPEUTICS, INC.
Reel/Frame 065970/0490 →
CHANGE OF NAME Recorded Mar 24, 2023
From: LYNDRA, INC.
To: LYNDRA THERAPEUTICS, INC.
Reel/Frame 063164/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2023
From: DUFOUR, DAVID C.
To: LYNDRA, INC.
Reel/Frame 063092/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2023
From: KANASTY, ROSEMARY; GRANT, TYLER; YANG, JUNG HOON; RYDE, ERIK ROBERT WALDEMAR
To: LYNDRA THERAPEUTICS, INC.
Reel/Frame 063093/0383 →
SECURITY INTEREST Recorded Jul 13, 2022
From: LYNDRA THERAPEUTICS, INC.
To: ISP HOLDINGS LLC
Reel/Frame 060499/0525 →
Continuity (3)
Provisional Application 62992075 · Mar 19, 2020
Provisional Application 62933211 · Nov 8, 2019
Related Publication 20220409528A1 · Dec 29, 2022
References Cited (136)
US 3531368A · Okamoto et al. · 1970 [cited by applicant]
US 3716614A · Watanabe et al. · 1973 [cited by applicant]
US 4304767A · Heller et al. · 1981 [cited by applicant]
US 4812012A · Terada et al. · 1989 [cited by applicant]
US 5002772A · Curatolo et al. · 1991 [cited by applicant]
US 5121329A · Crump · 1992 [cited by applicant]
US 5340433A · Crump · 1994 [cited by applicant]
US 7276252B2 · Payumo · 2007 [cited by applicant]
US 9884022B2 · Deshmukh et al. · 2018 [cited by applicant]
US 10182985B2 · Bellinger et al. · 2019 [cited by applicant]
US 10413507B2 · Zhang et al. · 2019 [cited by applicant]
US 10517819B2 · Bellinger et al. · 2019 [cited by applicant]
US 10517820B2 · Bellinger · 2019 [cited by applicant]
US 10532027B2 · Bellinger · 2020 [cited by applicant]
US 10596110B2 · Bellinger · 2020 [cited by applicant]
US 10610482B2 · Bellinger · 2020 [cited by applicant]
US 10716751B2 · Bellinger et al. · 2020 [cited by applicant]
US 10716752B2 · Bellinger et al. · 2020 [cited by applicant]
US 10849853B2 · Bellinger et al. · 2020 [cited by applicant]
US 10953208B2 · Zhang et al. · 2021 [cited by applicant]
US 11077056B2 · Bellinger et al. · 2021 [cited by applicant]
US 11083690B2 · Zhang et al. · 2021 [cited by applicant]
US 11246829B2 · Bellinger et al. · 2022 [cited by applicant]
US 11357723B2 · Bellinger et al. · 2022 [cited by applicant]
US 11389399B2 · Bellinger et al. · 2022 [cited by applicant]
US 11576859B2 · Kanasty et al. · 2023 [cited by applicant]
US 11576866B2 · Bellinger et al. · 2023 [cited by applicant]
US 11793751B2 · Grant et al. · 2023 [cited by applicant]
US 11992552B2 · Bellinger · 2024 [cited by applicant]
US 12023406B2 · Kanasty · 2024 [cited by applicant]
US 12109305B2 · Bellinger · 2024 [cited by applicant]
US 12142158B2 · Kanasty · 2024 [cited by applicant]
US 20050249798A1 · Mohammad · 2005 [cited by applicant]
US 20070037792A1 · Lang · 2007 [cited by applicant]
US 20070156248A1 · Marco et al. · 2007 [cited by applicant]
US 20070196416A1 · Li et al. · 2007 [cited by applicant]
US 20080131484A1 · Robinson et al. · 2008 [cited by applicant]
US 20100286628A1 · Gross · 2010 [cited by applicant]
US 20120269866A1 · Ali et al. · 2012 [cited by applicant]
US 20130017264A1 · Khandare et al. · 2013 [cited by applicant]
US 20130225778A1 · Goodrich et al. · 2013 [cited by applicant]
US 20130273135A1 · Brooks et al. · 2013 [cited by applicant]
US 20160317453A1 · Richey et al. · 2016 [cited by applicant]
US 20160317796A1 · Zhang et al. · 2016 [cited by applicant]
US 20170106099A1 · Bellinger et al. · 2017 [cited by applicant]
US 20180311154A1 · Kanasty · 2018 [cited by applicant]
US 20190125667A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190133936A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190209090A1 · Langer et al. · 2019 [cited by applicant]
US 20190231697A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190254966A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190262265A1 · Bellinger et al. · 2019 [cited by applicant]
US 20200281851A1 · Grant · 2020 [cited by examiner]
US 20210196627A1 · Grant et al. · 2021 [cited by applicant]
US 20220160642A1 · Bhise et al. · 2022 [cited by applicant]
US 20220192995A1 · Kanasty et al. · 2022 [cited by applicant]
US 20220387310A1 · Altreuter et al. · 2022 [cited by applicant]
US 20220387311A1 · Kanasty et al. · 2022 [cited by applicant]
US 20220387312A1 · Kanasty et al. · 2022 [cited by applicant]
US 20230039421A1 · Bellinger et al. · 2023 [cited by applicant]
US 20230190941A1 · Montezco et al. · 2023 [cited by applicant]
US 20240139102A1 · Grant · 2024 [cited by applicant]
US 20240252483A1 · Bhise · 2024 [cited by applicant]
US 20240335400A1 · Beguin · 2024 [cited by applicant]
US 20240342081A1 · Bellinger · 2024 [cited by applicant]
US 20240382418A1 · Kanasty · 2024 [cited by applicant]
US 20240390270A1 · Kanasty · 2024 [cited by applicant]
US 20240398701A1 · Kanasty · 2024 [cited by applicant]
US 20240423909A1 · Bellinger · 2024 [cited by applicant]
CN 101400363A · 2009 [cited by applicant]
CN 106573999A · 2017 [cited by applicant]
CN 108472249A · 2018 [cited by applicant]
CN 108697649A · 2018 [cited by applicant]
CN 109310639A · 2019 [cited by applicant]
CN 110022861A · 2019 [cited by applicant]
JP 2017505817A · 2017 [cited by applicant]
JP 2017524662A · 2017 [cited by applicant]
JP 2018515476A · 2018 [cited by applicant]
JP 2019501110A · 2019 [cited by applicant]
JP 2019503347A · 2019 [cited by applicant]
JP 2022553867A · 2022 [cited by applicant]
TW 201902459A · 2019 [cited by applicant]
WO 2015119653A1 · 2015 [cited by applicant]
WO 2015191920A1 · 2015 [cited by applicant]
WO 2015191925A1 · 2015 [cited by applicant]
WO 2017070612A1 · 2017 [cited by applicant]
WO 2017100367A1 · 2017 [cited by applicant]
WO 2017205844A2 · 2017 [cited by applicant]
WO 2018064630A1 · 2018 [cited by applicant]
WO 2018102799A1 · 2018 [cited by applicant]
WO 2018227147A1 · 2018 [cited by applicant]
WO 2019060458A1 · 2019 [cited by applicant]
WO 2021092484A1 · 2021 [cited by applicant]
WO 2021092486A1 · 2021 [cited by applicant]
WO 2021092487A1 · 2021 [cited by applicant]
WO 2021092491A1 · 2021 [cited by applicant]
WO 2023141524A2 · 2023 [cited by applicant]
WO 2024031023A2 · 2024 [cited by applicant]
WO 2024073752A2 · 2024 [cited by applicant]
Verma, S., et al., International Journal of Biological Macromolecules 64: 347-352 (Year: 2014). [cited by examiner]
Burt, H.M. et al. (1999). “Development of Copolymers of Poly(D,L-lactide) and Methoxypolyethylene Glycol as Micellar Carriers of Paclitaxel,” Colloids and Surfaces B: Biointerfaces 16(1-4):161-171. [cited by applicant]
European Examination Report, dated Jul. 15, 2025, for European Patent Application No. 20885040.4,6 pages. [cited by applicant]
Extended European Search Report, dated Jan. 17, 2024, for European Patent Application No. 20884024.9, 7 pages. [cited by applicant]
Extended European Search Report, dated Jan. 31, 2024, for European Patent Application No. 20885040.4, 13 pages. [cited by applicant]
Extended European Search Report, dated Jan. 9, 2024, for European Patent Application No. 20885272.3, 7 pages. [cited by applicant]
Extended European Search Report, dated Nov. 29, 2023, for European Patent Application No. 20884800.2, 7 pages. [cited by applicant]
Felix Lanao, R.P. et al. (Aug. 2013, E-pub Mar. 1, 2013). “Physicochemical Properties and Applications of Poly (Lactic-Co-Glycolic Acid) for Use in Bone Regeneration,” Tissue Eng Part B Rev. 19(4):380-390. [cited by applicant]
Makadia, H.K. et al. (2011). “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymers 3:1377-1397. [cited by applicant]
Manna, S. et al. (2018). “Improved Design and Characterization of PLGA/PLA-Coated Chitosan Based Micro-Implants for Controlled Release of Hydrophilic Drugs,” International Journal of Pharmaceutics, 547(1-2):122-132. [cited by applicant]
Moroishi, H et al. (2018). “PLA- and PLA/PLGA-Emulsion Composite Biomaterial Sheets for the Controllable Sustained Release of Hydrophilic Compounds,” Materials, 11(12)2588: 12 pages. [cited by applicant]
Partial Supplementary European Search Report, dated Nov. 6, 2023, for European Patent Application No. 20885040.4, 14 pages. [cited by applicant]
Poly(D, L-Lactide-co-glycolide), Poly(D, L-lactide-co-glycolide), 50:50, IV 0.40 dl/g, acid-terminated. (May 29, 2017). https://web.archive.org/web/20170529103446/https://www.polysciences.com/defau1Upoly-d-l-lactide-co-… [cited by applicant]
Poly(D,L-lactic acid), IV 2.0 DUG. Poly(dl-lactic acid) i.v. 2.0-2.8dl/g I Polysciences, Inc. (2016, Aug. 24). https://web.archive.org/web/20160824222556/https://www.polysciences.com/defau1Upolydl-lactic-acid-iv-20-28dl… [cited by applicant]
Alhnan, M.A. et al. (Aug. 2016; e-published on May 18, 2016). “Emergence of 3D PrintedOpportunities and Challenges,” Pharm. Res. 33(8):1817-1832, 38 pages. [cited by applicant]
CAS No. 112945-52-5 (2017). “Silicon Dioxide,” 5 pages. [cited by applicant]
CAS No. 9003-11-6 (Dec. 21, 2022). “Polyethylene-Polyproylene Glycol,” 2 pages. [cited by applicant]
Haslauer, C.M. et al. (Jul. 2015; e-published on Sep. 17, 2014). “Translating Textiles to Tissue Engineering: Creation and Evaluation of Microporous, Biocompatible, Degradable Scaffolds Using Industry Relevant Manufactu… [cited by applicant]
International Preliminary Report on Patentability, issued May 10, 2022, for PCT Application No. PCT/US/2020/059533, filed Nov. 6, 2020, 7 pages. [cited by applicant]
International Preliminary Report on Patentability, issued May 10, 2022, for PCT Application No. PCT/US/2020/059534, filed Nov. 6, 2020, 6 pages. [cited by applicant]
International Preliminary Report on Patentability, issued May 10, 2022, for PCT Application No. PCT/US/2020/059536, filed Nov. 6, 2020, 7 pages. [cited by applicant]
International Preliminary Report on Patentability, issued May 10, 2022, for PCT Application No. PCT/US/2020/059537, filed Nov. 6, 2020, 8 pages. [cited by applicant]
International Preliminary Report on Patentability, issued May 10, 2022, for PCT Application No. PCT/US/2020/059541, filed Nov. 6, 2020, 16 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Feb. 2, 2021, for PCT Application No. PCT/US/2020/059534, filed Nov. 6, 2020, 8 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Feb. 4, 2021, for PCT Application No. PCT/US/2020/059533, filed Nov. 6, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Feb. 4, 2021, for PCT Application No. PCT/US/2020/059541, filed Nov. 6, 2020, 19 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Mar. 25, 2021, for PCT Application No. PCT/US/2020/059536, filed Nov. 6, 2020, 10 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Mar. 25, 2021, for PCT Application No. PCT/US/2020/059537, filed Nov. 6, 2020, 11 pages. [cited by applicant]
Khaled, S.A. et al. (2014). “Desktop 3D Printing of Controlled Release Pharmaceutical Bilayer Tablets,” International Journal of Pharmaceutics 17 pages. [cited by applicant]
Mukherji, G. et al. (2003). “Enteric Coating for Colonic Delivery,” Chapter 18 in Modified-Release Drug Delivery Technology 126:223-232. [cited by applicant]
Singh, S.P. et al. (2011). “Measurement and Analysis of Vibration and Temperature Levels in Global Intermodal Container Shipments on Truck, Rail and Ship,” Packaging Technol. Science, 12 pages. [cited by applicant]
U.S. Appl. No. 17/774,128, filed May 3, 2022, Montezco et al. br(issued by the Office on Sep. 21, 2004). [cited by applicant]
Ursan, I.D. et al. (Mar.-Apr. 2013). “Three-Dimensional Drug Printing: A Structured Review,” J. Am. Pharm. Assoc. 53(2):136-144. [cited by applicant]
Yu, D.G. et al. (Sep. 2008). “Three-Dimensional Printing in Pharmaceutics: Promises and Problems,” J. Pharm. Sci. 97(9):3666-3690. [cited by applicant]
European Examination Report dated Oct. 24, 2025, for European Patent Application No. 20884800.2, 4 pages. [cited by applicant]
Evonik Industries. (Jul. 2015). “RESOMER Product Range” Evonik Industries 2.6, 4 pages. [cited by applicant]
Martin, L.M. et al. (2014). “Applications of Polyethylene Oxide (POLYOX) in Hydrophilic Matrices,” Chapter 5 in Hydrophilic Matrix Tablets for Oral Controlled Release, pp. 123-141, 22 pages. [cited by applicant]